Vor Biopharma’s Telitacicept Pipeline Highlights MG, Ocular MG, Sjögren’s Focus at Citi Summit

Vor Biopharma’s leadership outlined its strategic focus on advancing Telitacicept through clinical trials for Myasthenia Gravis (MG) and ocular MG, alongside a Sjögren’s disease program, during Citigroup’s Biopharma Back to School Summit in September 2026. The company, which in-licensed Telitacicept from RemeGen in mid-2025, emphasized its near-term catalyst in MG, where the drug has shown efficacy in a Chinese Phase III study with a 4.6-point improvement in MG-ADL scores over placebo. The trial, completed ahead of schedule, is expected to deliver top-line results in the first half of 2027, following a 24-week follow-up period. A planned Phase III for ocular MG is also set for the first half of 2027, leveraging the same investigator network and infrastructure as the MG program. The ocular MG indication represents a $1 billion-plus opportunity, with about 80% of patients progressing to generalized MG. Meanwhile, Vor Biopharma’s Sjögren’s disease program, which began enrolling patients in March 2025, is a 48-week trial with primary endpoints measured via ESSDAI and ESSPRI scoring scales. The trial is designed to enroll 250 patients, benefiting from investigators previously trained by Novartis. The company’s stock traded around $25.05 on the day of the summit, up 3.34% from its prior close, though it dipped slightly in after-hours trading. The MG market alone is valued at roughly $3 billion in the U.S. and projected to exceed $10 billion by decade-end, while Sjögren’s disease represents a multi-billion-dollar opportunity. Telitacicept’s mechanism—targeting a 2-to-1 ratio of BAFF to APRIL—positions it as a differentiated approach in the biopharma space, with safety profiles expected to include minor increases in urinary and respiratory infections but no hospitalizations or severe outcomes. The company’s commercial head noted the potential for weekly subcutaneous dosing with home self-administration options, tailored to patient needs. Analysts at Citigroup highlighted the drug’s clinical separation in MG trials, with Efgartigimod showing a ~67% rate of a two-point MG-ADL improvement in benchmark studies.